A Phase 1 Study of BBO-10203 in People With Advanced Solid Tumors

Full Title

A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors

Purpose

Researchers want to find the best dose of BBO-10203 to use in people with advanced solid tumors. The people in this study have one of these types of cancer that has spread (metastasized):

• Breast cancer that makes an excess amount of the HER2 protein.
• Breast cancer that is negative for HER2 but is fueled by estrogen and/or progesterone.
• Non-small cell lung cancer (NSCLC) with a mutation (change) in the KRAS gene.
• Colorectal cancer with a KRAS mutation.

BBO-10203 may slow or stop cancer growth by blocking the interaction between two proteins. It is taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-4226.